
GENinCode specializes in risk assessment and prediction of cardiovascular disease , thrombosis and familial hypercholesterolemia . Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States.
GEN inCode provides advanced genomic technology, products and recommendations fully validated by our scientific and clinical team.
Our goal is to provide doctors and health care practitioners with advanced health information that combines both traditional clinical measures with a patient’s genetic information to provide a comprehensive risk assessment and clinical recommendation to help decision-making. Our technology helps select the optimal treatment pathway and informs and educates patients to become more aware of their cardiovascular risk helping patient adherence and empowerment to better manage their health.
GEN inCode technology and advanced genomic products provide information that helps patients and healthcare practitioners to assess and predict the onset of cardiovascular disease, thrombosis, and the diagnosis of Familial Hypercholesterolemia. Our online reporting system SITAB® helps inform doctors of their patients’ health risk enabling patient behavioral and lifestyle changes alongside delivering the most effective therapies and treatment pathways.
GEN inCode provides advanced genomic technology, products and recommendations fully validated by our scientific and clinical team.
Our goal is to provide doctors and health care practitioners with advanced health information that combines both traditional clinical measures with a patient’s genetic information to provide a comprehensive risk assessment and clinical recommendation to help decision-making. Our technology helps select the optimal treatment pathway and informs and educates patients to become more aware of their cardiovascular risk helping patient adherence and empowerment to better manage their health.
GEN inCode technology and advanced genomic products provide information that helps patients and healthcare practitioners to assess and predict the onset of cardiovascular disease, thrombosis, and the diagnosis of Familial Hypercholesterolemia. Our online reporting system SITAB® helps inform doctors of their patients’ health risk enabling patient behavioral and lifestyle changes alongside delivering the most effective therapies and treatment pathways.
Location: United Kingdom, England, Oxford
Employees: 11-50
Phone: +44 1865 955847
Total raised: $4.49M
Founded date: 2018
Investors 2
Date | Name | Website |
- | Bioscience... | bioscience... |
18.05.2023 | Cambridge ... | cic.vc |
Funding Rounds 1
Date | Series | Amount | Investors |
01.09.2020 | - | $4.49M | Maven Capi... |
Mentions in press and media 6
Date | Title | Description |
20.09.2024 | DISCOVER FH collaboration with Family Heart Foundation®, UT Southwestern, and Partners | GEN inCode PLC LIPID inCode®, tests patients to identify familial hypercholesterolemia and prevent cardiovascular disease OXFORD, UNITED KINGDOM, September 20, 2024 /EINPresswire.com/ -- GENinCode Plc (LSE AIM: GENI), the genetics company f... |
29.08.2024 | CARDIO inCode-Score presentation on polygenic risk of Coronary Heart Disease at the 2024 ESC Annual Congress, London | GENinCode CARDIO inCode-Score IRVINE, US, August 29, 2024 /EINPresswire.com/ -- GENinCode US Inc, the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, announces the presentation by Kaiser Permanente... |
08.09.2020 | GEN inCode completa una ronda de financiación institucional de 3 millones de libras esterlinas | 08/09/2020 Nota de prensa GEN INCODE COMPLETA UNA RONDA DE FINANCIACIÓN INSTITUCIONAL DE 3 MILLONES DE LIBRAS ESTERLINAS. GEN inCode – sociedad de capital privado de inteligencia artificial especializada en la prevención de enfermedades ... |
27.08.2020 | Maven co-leads £3.4m funding round for Gen inCode | Maven Capital Partners has invested £1.5 million in Gen inCode, a genetic testing business specialising in the risk assessment and prediction of cardiovascular disease. Gen inCode raised in total £3.4 million, where Maven invested alongside... |
- | Downing Ventures Invests £1.5m in A.I. Company That Prevents Cardiovascular Disease | Downing Ventures is delighted to announce completion of a £3.4 million round with a £1.5 million investment in GEN inCode UK Limited alongside Maven and other existing private shareholders. The investment propels GEN inCode to international... |
- | The time to put the spotlight on Healthcare is now | As Covid-19 continues to dominate the global agenda, early-stage UK technology companies in the healthcare and life sciences sectors are at the forefront of making the world a safer and more secure place to live in. The need for accelera... |